CVE:IGXIntelGenx Technologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IntelGenx Technologies Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$0.28 0.00 (0.00 %) (As of 07/3/2020 03:23 PM ET) Add Compare Share Today's RangeC$0.28Now: C$0.28▼C$0.2850-Day RangeC$0.27MA: C$0.31▼C$0.4452-Week RangeC$0.16Now: C$0.28▼C$0.94Volume1,800 shsAverage Volume144,092 shsMarket CapitalizationC$30.87 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0045/2018, INT0046/2018. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for IntelGenx Technologies. Previous Next 2.6 Community Rank Outperform VotesIntelGenx Technologies has received 92 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIntelGenx Technologies has received 86 “underperform” votes. (Add your “underperform” vote.)Community SentimentIntelGenx Technologies has received 51.69% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about IntelGenx Technologies and other stocks. Vote “Outperform” if you believe IGX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IGX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIntelGenx Technologies does not currently pay a dividend.Dividend GrowthIntelGenx Technologies does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IntelGenx Technologies insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IntelGenx Technologies are expected to grow in the coming year, from C($0.10) to C$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IntelGenx Technologies is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IntelGenx Technologies is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntelGenx Technologies has a P/B Ratio of 11.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.65 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:IGX Previous Symbol CUSIPN/A CIKN/A Webwww.intelgenx.com Phone514-331-7440Debt Debt-to-Equity Ratio299.01 Current Ratio0.73 Quick Ratio0.66Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$528,000.00 Price / Sales58.47 Cash FlowC$0.04 per share Price / Cash Flow6.75 Book ValueC$0.03 per share Price / Book11.20Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees38 Outstanding Shares110,260,000Market CapC$30.87 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable TSXV:IGX Rates by TradingView Receive IGX News and Ratings via Email Sign-up to receive the latest news and ratings for IGX and its competitors with MarketBeat's FREE daily newsletter. IntelGenx Technologies (CVE:IGX) Frequently Asked Questions How has IntelGenx Technologies' stock been impacted by COVID-19 (Coronavirus)? IntelGenx Technologies' stock was trading at C$0.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IGX stock has decreased by 48.1% and is now trading at C$0.28. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of IntelGenx Technologies? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IntelGenx Technologies in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for IntelGenx Technologies. When is IntelGenx Technologies' next earnings date? IntelGenx Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for IntelGenx Technologies. How were IntelGenx Technologies' earnings last quarter? IntelGenx Technologies Corp. (CVE:IGX) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.01. The business earned $0.27 million during the quarter, compared to analysts' expectations of $0.14 million. View IntelGenx Technologies' earnings history. Has IntelGenx Technologies been receiving favorable news coverage? News stories about IGX stock have been trending somewhat negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. IntelGenx Technologies earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about IntelGenx Technologies. Who are some of IntelGenx Technologies' key competitors? Some companies that are related to IntelGenx Technologies include Immunoprecise Antibodies (IPA), Predictive Technology Group (PRED), Arix Bioscience (ARIX), Senesco Technologies (ELOX), CorMedix (CRMD), 22nd Century Group (XXII), Ampliphi Biosciences (APHB), Ampio Pharmaceuticals (AMPE), Actinium Pharmaceuticals (ATNM), Helix Biopharma (HBP), Oncolytics Biotech (ONC), AquaBounty Technologies (AQB), Ibio (IBIO), Navidea Biopharmaceuticals (NAVB) and Orgenesis (ORGS). View all competitors. What other stocks do shareholders of IntelGenx Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other IntelGenx Technologies investors own include IntelGenx Technologies (IGXT), Aurora Cannabis (ACB), New Age Brands (NF), Capstone Mining (CS), Hanesbrands (HBI), Tilray (TLRY), ACADIA Pharmaceuticals (ACAD), Auscann Group (AC8), Cameco (CCJ) and Baylin Technologies (BYL). Who are IntelGenx Technologies' key executives? IntelGenx Technologies' management team includes the following people: Dr. Horst G. Zerbe, Founder, Chairman, CEO & Chairman of Scientific Advisory Board (Age 72)Mr. Andre Godin C.A., CPA, CPA, CA, Exec. VP, Pres & CFO (Age 55)Dr. Dana Matzen, VP of Bus. & Corp. Devel. (Age 41)Ms. Nadine Paiement, Vice-Chair of Scientific Advisory Board and VP of R&D (Age 42)Ms. Ingrid Zerbe, Co-Founder & Corp. Sec. (Age 65) What is IntelGenx Technologies' stock symbol? IntelGenx Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IGX." How do I buy shares of IntelGenx Technologies? Shares of IGX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is IntelGenx Technologies' stock price today? One share of IGX stock can currently be purchased for approximately C$0.28. How big of a company is IntelGenx Technologies? IntelGenx Technologies has a market capitalization of C$30.87 million and generates C$528,000.00 in revenue each year. IntelGenx Technologies employs 38 workers across the globe. What is IntelGenx Technologies' official website? The official website for IntelGenx Technologies is www.intelgenx.com. How can I contact IntelGenx Technologies? The company can be reached via phone at 514-331-7440. This page was last updated on 7/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
